Combinatorial Incorporation of Enhancer-blocking Components of the Chicken Beta-globin 5'HS4 and Human T-cell Receptor Alpha/delta BEAD-1 Insulators in Self-inactivating Retroviral Vectors Reduces Their Genotoxic Potential

Overview

Journal Stem Cells

Publisher Oxford University Press

Specialties Cell Biology
Reproductive Medicine

Date 2008 Sep 13

PMID 18787211

Citations 38

Authors

Ali Ramezani

Teresa S Hawley

Robert G Hawley

Affiliations

Soon will be listed here.

Abstract

Insertional mutagenesis by retroviral vectors has emerged as a serious impediment to the widespread application of hematopoietic stem cell gene transfer for the treatment of hematologic diseases. Here we report the development of a 77-base pair element, FII/BEAD-A (FB), which contains the minimal enhancer-blocking components of the chicken beta-globin 5'HS4 insulator and a homologous region from the human T-cell receptor alpha/delta BEAD-1 insulator. With a new flow cytometry-based assay, we show that the FB element is as effective in enhancer-blocking activity as the prototypical 1.2-kilobase 5'HS4 insulator fragment. When incorporated into the residual U3 region of the 3' long terminal repeat (LTR) of a self-inactivating (SIN) gammaretroviral vector, the FB element was stably transferred to the 5' LTR during reverse transcription, flanking the integrated transgene expression cassette. Notably, using a recently established in vitro insertional mutagenesis assay involving primary murine hematopoietic cells, we found that SIN gammaretroviral vectors, as well as SIN lentiviral vectors, containing the FB element exhibited greatly reduced transforming potential-to background levels under the experimental conditions used-compared with their unshielded counterparts. These results suggest that the FB element-mediated enhancer-blocking modification is a promising approach to dramatically improve the safety of retroviral vectors for therapeutic gene transfer.

Citing Articles

Advancements in -Based Anti-Tumor Gene Therapy Research.

Peng Y, Bai J, Li W, Su Z, Cheng X Molecules. 2024; 29(22).

PMID: 39598704 PMC: 11596491. DOI: 10.3390/molecules29225315.

Mechanisms and Delivery of tRNA Therapeutics.

Ward C, Beharry A, Tennakoon R, Rozik P, Wilhelm S, Heinemann I Chem Rev. 2024; 124(12):7976-8008.

PMID: 38801719 PMC: 11212642. DOI: 10.1021/acs.chemrev.4c00142.

Quantitative spatial and temporal assessment of regulatory element activity in zebrafish.

Bhatia S, Kleinjan D, Uttley K, Mann A, Dellepiane N, Bickmore W Elife. 2021; 10.

PMID: 34796872 PMC: 8604437. DOI: 10.7554/eLife.65601.

A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies.

Zittersteijn H, Harteveld C, Klaver-Flores S, Lankester A, Hoeben R, Staal F Front Genome Ed. 2021; 2:617780.

PMID: 34713239 PMC: 8525365. DOI: 10.3389/fgeed.2020.617780.

Coordinated β-globin expression and α2-globin reduction in a multiplex lentiviral gene therapy vector for β-thalassemia.

Nualkaew T, Sii-Felice K, Giorgi M, McColl B, Gouzil J, Glaser A Mol Ther. 2021; 29(9):2841-2853.

PMID: 33940155 PMC: 8417505. DOI: 10.1016/j.ymthe.2021.04.037.

References

Ramezani A, Hawley T, Hawley R . Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol Ther. 2000; 2(5):458-69. DOI: 10.1006/mthe.2000.0190. View

Ott M, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U . Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006; 12(4):401-9. DOI: 10.1038/nm1393. View

Kustikova O, Fehse B, Modlich U, Yang M, Dullmann J, Kamino K . Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science. 2005; 308(5725):1171-4. DOI: 10.1126/science.1105063. View

Yannaki E, Tubb J, Aker M, Stamatoyannopoulos G, Emery D . Topological constraints governing the use of the chicken HS4 chromatin insulator in oncoretrovirus vectors. Mol Ther. 2002; 5(5 Pt 1):589-98. DOI: 10.1006/mthe.2002.0582. View

Niwa H, Yamamura K, Miyazaki J . Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991; 108(2):193-9. DOI: 10.1016/0378-1119(91)90434-d. View

Brown B, Shi C, Rawle F, Tinlin S, McKinven A, Hough C . Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice. J Thromb Haemost. 2004; 2(1):111-8. DOI: 10.1111/j.1538-7836.2004.00552.x. View

Modlich U, Bohne J, Schmidt M, von Kalle C, Knoss S, Schambach A . Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood. 2006; 108(8):2545-53. PMC: 1895590. DOI: 10.1182/blood-2005-08-024976. View

Hawley T, Telford W, Ramezani A, Hawley R . Four-color flow cytometric detection of retrovirally expressed red, yellow, green, and cyan fluorescent proteins. Biotechniques. 2001; 30(5):1028-34. DOI: 10.2144/01305rr01. View

Du Y, Jenkins N, Copeland N . Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood. 2005; 106(12):3932-9. PMC: 1895096. DOI: 10.1182/blood-2005-03-1113. View

10.

Calmels B, Ferguson C, Laukkanen M, Adler R, Faulhaber M, Kim H . Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood. 2005; 106(7):2530-3. PMC: 1895268. DOI: 10.1182/blood-2005-03-1115. View

11.

Modlich U, Schambach A, Brugman M, Wicke D, Knoess S, Li Z . Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia. 2008; 22(8):1519-28. DOI: 10.1038/leu.2008.118. View

12.

Hawley R, Lieu F, Fong A, Hawley T . Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994; 1(2):136-8. View

13.

Hematti P, Hong B, Ferguson C, Adler R, Hanawa H, Sellers S . Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2004; 2(12):e423. PMC: 529319. DOI: 10.1371/journal.pbio.0020423. View

14.

Hawley R . Progress toward vector design for hematopoietic stem cell gene therapy. Curr Gene Ther. 2002; 1(1):1-17. DOI: 10.2174/1566523013348904. View

15.

Kraunus J, Schaumann D, Meyer J, Modlich U, Fehse B, Brandenburg G . Self-inactivating retroviral vectors with improved RNA processing. Gene Ther. 2004; 11(21):1568-78. DOI: 10.1038/sj.gt.3302309. View

16.

Morishita K, Parker D, Mucenski M, Jenkins N, Copeland N, Ihle J . Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell. 1988; 54(6):831-40. DOI: 10.1016/s0092-8674(88)91175-0. View

17.

Hacein-Bey-Abina S, von Kalle C, Schmidt M, McCormack M, Wulffraat N, Leboulch P . LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003; 302(5644):415-9. DOI: 10.1126/science.1088547. View

18.

Zhong X, Krangel M . An enhancer-blocking element between alpha and delta gene segments within the human T cell receptor alpha/delta locus. Proc Natl Acad Sci U S A. 1997; 94(10):5219-24. PMC: 24659. DOI: 10.1073/pnas.94.10.5219. View

19.

Modlich U, Kustikova O, Schmidt M, Rudolph C, Meyer J, Li Z . Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood. 2005; 105(11):4235-46. DOI: 10.1182/blood-2004-11-4535. View

20.

Ramezani A, Hawley T, Hawley R . Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood. 2003; 101(12):4717-24. DOI: 10.1182/blood-2002-09-2991. View